There is an established, albeit poorly-understood link between psychosis and metabolic abnormalities such as altered glucose metabolism and dyslipidemia, which often precede the initiation of antipsychotic treatment. It is known that obesity-associated metabolic disorders are promoted by peripheral activation of the endocannabinoid system (ECS). Our recent data suggest that ECS dysregulation may also play a role in psychosis. With the aim of characterizing the involvement of the central and peripheral ECSs and their mutual associations, here we performed a combined neuroimaging and metabolomic study in patients with first-episode psychosis (FEP) and healthy controls (HC). Regional brain cannabinoid receptor type 1 (CB1R) availability was quantified in two, independent samples of patients with FEP (n=20 and n=8) and HC (n=20 and n=10), by applying 3D positron emission tomography (PET), using two radiotracers, [ 11 C]MePPEP and [ 18 F]FMPEP-d2. Ten endogenous endocannabinoids or related metabolites were quantified in serum, drawn from these individuals during the same imaging session. Circulating levels of arachidonic acid and oleyl ethanolamide were reduced in FEP individuals, but not in those who were predominantly medication-free. In HC, there was an inverse association between levels of circulating arachidonoyl glycerol, anandamide, oleyl ethanolamide and palmitoyl ethanolamide, and CB1R availability in the posterior cingulate cortex. This phenomenon was, however, not observed in FEP patients. Our data thus provide evidence of cross-talk and dysregulation between peripheral endocannabinoids and central CB1R availability in FEP.
Introduction
Psychotic disorders are associated with a reduced life expectancy of 15-20 years 1 , which is in part due to the high prevalence of cardiovascular disease, type 2 diabetes (T2DM) and metabolic syndrome 2, 3 . Unhealthy lifestyles and pharmacological side effects have been suggested to be a major cause of these mortality rates 4 . However, abnormal glucose homeostasis, hyperinsulinemia, dyslipidemia and accumulation of visceral fat are already evident in drug-naïve first episode psychosis (FEP) patients, independent of obesity 5, 6 .
The mechanisms underlying the development of metabolic co-morbidities in psychosis are poorly understood. There is evidence that anti-psychotic medication, particularly clozapine, leads to rapid weight gain 7 , while co-treatment with metformin can help reduce this 8 . A recent study in FEP patients identified changes in specific circulating lipids, which are known to be associated with non-alcoholic fatty liver disease (NAFLD) and T2DM risk, prior to weight gain 9 .
There is emerging evidence suggesting that the endocannabinoid system (ECS) might be dysregulated in various psychiatric disorders, including schizophrenia [10] [11] [12] [13] [14] . Furthermore, the ECS has been shown to play a role in metabolic disorders [15] [16] [17] . Taken together, these findings suggest that the dysregulation of the ECS could play a role in the development or progression of metabolic co-morbidities observed in psychosis.
The ECS is composed of (1) cannabinoid receptors type 1 (CB1R) and type 2 (CB2R), (2) lipidderived endocannabinoid ligands with affinity to these or other receptors, and (3) enzymes involved in the synthesis and degradation of these ligands 18, 19 . The CB1Rs are found in the central nervous system (CNS) as well as in the periphery, throughout the gastrointestinal tract, liver, adipose tissue and adrenal glands 20, 21 . In the CNS, the CB1R plays an important role in cognition 22 and has been implicated in mood and anxiety disorders 23, 24 . Recent evidence from both our group and others suggests that central CB1R availability is altered psychosis [25] [26] [27] . We recently showed that CB1R availability is altered in patients with psychosis, where greater reductions in CB1R levels are associated with greater symptom severity and poorer cognitive functioning 27 . There is also evidence that endogenous cannabinoid ligands which act as CB1R agonists are elevated in the cerebrospinal fluid of medication-naïve psychotic patients 11, 14, 28, 29 .
Metabolomics approaches have identified systemic metabolic changes in the context of psychosis 9, 30, 31 and neurodegenerative disorders [32] [33] [34] , suggesting that a strong link exists between the circulating metabolome and diseases of the central nervous system. Several studies have demonstrated that psychotic patients have dysregulated metabolic profiles, including dyslipidemia and dysglycemia 35, 36 . Intriguingly, an imbalance of peripheral endocannabinoids has also been associated with various metabolic disorders, including diabetes and obesity 37, 38 .
Furthermore, changes in blood endocannabinoid levels are associated with improvement in symptoms of psychosis 39 , which could imply that endocannabinoid signaling may not only be dysregulated in the central nervous system of psychotic patients, but also in the periphery 12 . There is an association between cannabis use and disturbances of the central ECS, providing further evidence for potential cross-talk between the endogenous peripheral and central ECSs 40, 41 .
However, to our knowledge, there are no data investigating the link between peripheral endocannabinoid levels and brain CB1R availability in healthy individuals or in psychosis. Therefore, we aimed to investigate the association between peripheral endocannabinoids and brain CB1R availability. To this end, we quantified serum endocannabinoids using liquidchromatography triple-quadrupole mass spectrometry (LC-QqQMS) and brain CB1R availability in a case-control setting, which included FEP patients and matched healthy controls.
Methods

Ethics statement
Ethical approvals were obtained from respective study sites in Finland (ETMK 98/180/2013) and 5 England (14/LO/1289). Subjects' capacities for consent were assessed and informed, written consent was obtained from all volunteers.
Study design and participants
The study setting was described in detail previously 27 . CB1R availability was investigated at two PET centers using independent samples; Turku (n = 11, HC; n = 8, FEP) and London (n = 23, HC; n = 20, FEP). However, some subjects were excluded due to increases in AG levels, caused by sample handling resulting in the following subjects being included in the analysis: Turku (n = 10, HC; n = 8, FEP) and London (n = 15, HC; n = 11, FEP) ( Table 1) . Given putative sex differences in CB1R availability 42 , we only investigated males to remove sex as a source of variability. Corresponding studies in females are currently ongoing.
FEP patients met the following inclusion criteria: (i) DSM-IV diagnosis of a psychotic disorder, determined by the SCID-I/P; (ii) illness duration of less than 3 years; and (iii) male sex. In Turku, FEP volunteers were already taking antipsychotic medication prior to the start of the study and had diagnoses of affective or non-affective psychosis. In London, FEP volunteers were, with the exception of two individuals, medication-free from all pharmacological treatments for at least 6 months and had diagnoses of schizophrenia or schizoaffective disorder (DSM-IV criteria).
Healthy volunteers had no current/lifetime history of any Axis-I disorder as determined by the SCID-I/P and were matched for age (age +/-3 years) and sex (male). Exclusion criteria for all volunteers were: (i) current/lifetime history of substance abuse/dependence; (ii) substance use within the last month; (iii) positive screen on toxicology tests for cannabis and other substances.
CB1R availability PET imaging
The full methods for PET CB1R imaging were described in detail previously 27 . However, a concise description for both studies, Turku and London, is provided here.
Turku study. [ 18 F]FMPEP-d2 was synthesized as described previously 43 , with slight modifications.
The radiochemical purity was greater than 95% and the molar radioactivity was greater than 500 GBq/μmol at the end of synthesis resulting in an injected tracer mass below 200 ng.
Positron emission scans were done in three-dimensional list-mode, in increasing frame duration for a total scan range of 0-120 min, with a brain-dedicated high-resolution research tomograph (ECAT HRRT, Siemens Medical Solutions, Kemnath, Germany), after a bolus injection of [ 18 F]FMPEP-d2 (201 ± 11.1 MBq). Attenuation correction of PET was applied using a 137 Cs point source. Arterial plasma activity was measured continuously for the first 3.5 minutes, and discretely thereafter at 4. 5, 7.5, 11,15, 20, 25, 30, 35, 40, 45, 50 and 60 min. Arterial input was corrected for tracer metabolite activity measured using thin layer chromatography and digital autoradiography. The resulting metabolite free arterial input was corrected for temporal delay between blood and PET tissue measurements. Motion correction between PET frames was done by realigning the PET frames to a single reference frame with the most uptake on average. Wholebrain T1-weighted MRI images were acquired by a Philips 3T Ingenuity PET/MR hybrid scanner.
The individual T1-weighted images were co-registered to the sum of the realigned PET frames.
Inverse normalization parameters obtained from normalizing the co-registered T1-weighted images to MNI space were used to fit the Hammersmith anatomical atlas to the PET frames (Hammers et. al 2003) . Data pre-processing was performed using Statistical Parametric Mapping 12 (http://www.fil.ion.ucl.ac.uk/spm) and MATLAB R2014b (Mathworks Inc., Natick, MA).
London study. Continuous, 90-minute PET scans were acquired on a PET/CT (Hi-Rez Biograph 6 CT44931; Siemens Medical Solutions, Kemnath, Germany) in three-dimensional mode, after bolus injection of 314 ± 34.4 MBq of [ 11 C]MePPEP, as previously described [44] [45] [46] . CT scans were acquired prior to each PET scan for correction of attenuation and scatter. Continuous arterial blood sampling took place for the first 15 minutes of the scan which was followed by discrete blood sampling at 2, 5, 10, 15, 20, 25, 35, 40, 50, 60, 70, 80 and 90 minutes after radioligand injection.
Images were reconstructed with filtered back-projection including corrections for attenuation and scatter. There were no significant group differences in injected mass, injected activity, or specific activity. To aid anatomical localization, each volunteer received a high-resolution structural 3D T1-weighted magnetic resonance scan acquired on a General Electric MR750 3T scanner (MR750; GE Healthcare, Chicago, IL).
Data pre-processing was performed using a combination of Statistical Parametric Mapping 12 (http://www.fil.ion.ucl.ac.uk/spm) and FSL (http://www.fsl.fmrib.ox.ac.uk/fsl) functions, as implemented in MIAKAT (http://miakat.org). Motion correction was applied to non-attenuationcorrected images 47 . Non-attenuated corrected frames were realigned to a single "reference" frame (corresponding to that with the highest number of counts) by employing a mutual information algorithm. The transformation parameters were then applied to the corresponding attenuatedcorrected dynamic images, creating a movement-corrected dynamic image which was used for subsequent analysis. Realigned frames were then summated to create single-subject motioncorrected maps which were then used for MRI and PET co-registration, prior to PET data quantification. T1-weighted structural images were co-registered to the PET image using rigid body transformation. Normalization parameters were obtained by warping the co-registered structural MRI to MNI space (International Consortium for Brain Mapping ICBM/MNI) using bias-corrected segmentation. The inverse of these parameters was used to fit a neuroanatomical atlas to each individual PET scan using the Hammersmith atlas 48 . Whole blood time-activity curves (TACs) were fitted using a multi-exponential function as derived by Feng's model 49 . For each scan, a time delay was fitted and applied to the input functions (both parent and whole blood TACs) to account for any temporal delay between blood sample measurement and target tissue data. Regions of interest were harmonized with the Turku PET dataset.
In both Turku and London studies, CB1R availability was indexed using the volume of distribution (VT ml/cm 3 ) of the respective PET tracer, as calculated using the Logan graphical method with a metabolite-corrected arterial plasma input function. The resulting model was validated as described previously 27, 50 . The temporal lobe, frontal lobe, anterior cingulate cortex, posterior cingulate cortex, striatum, parietal lobe, occipital lobe, putamen, nucleus caudatus, insula, amygdala, and whole brain were chosen as regions of interest for PET. Hippocampal, amygdala, superior temporal gyral, superior frontal, middle frontal, inferior frontal and orbitofrontal subregions were included to explore regional differences within relevant regions of interest (ROI).
Due to the use of different PET tracers used in both sites, the CB1R availability data was scaled to unit variance and zero mean within each study, when analyzed together.
Analysis of serum endocannabinoids
The following peripheral endocannabinoids and related structures were measured using a Louis, MO). Initially, the internal standards (10 µL, 100 ng/mL, of THC-COOH-d9, 2-AG-d5, NADA-d8, and AEA-d8 in EtOH) were added to 200 µL of serum in silylated 2 mL glass chromatography vials. The proteins were then precipitated using acetonitrile (400 µL) containing 0.1% v/v formic acid (LC-grade, Sigma-Aldrich). This was done in metal and glass syringes to ensure no contamination from plastic. The samples were then briefly vortexed and placed at -20 °C for 30 minutes. The samples were then centrifuged (10,000 g, 4 °C) for 10 minutes. The supernatant was then removed and placed in fresh silylated vials and stored for no more than 24 hours before solid phase extraction (SPE) of the endocannabinoids. The endocannabinoids were separated using ultra-high-performance liquid chromatography (UHPLC). The two eluent solvents were (i) H 2 O (1% v/v acetic acid) and (ii) ACN. The gradient was set up as follows: the initial conditions were 70% B for 4.5 minutes increasing to 80% B by 7 minutes. By 8 minutes, the gradient was increased to 95% B and held there for 10 minutes. The gradient was reduced to the starting conditions by 10.5 minutes and the column flushed with a minimum of 10 column volumes. The flow rate was set at 0.5 mL/min throughout the run and the column temperature set to 60 °C. The column used for the separation was a Waters ACQUITY BEH reverse phase C18 column (130 Å, 1.7 µm, 2.1 mm × 50 mm). The injection volume was 10 µL.
The needle was washed three times both before and after the injection with two solvents: (i) IPA:ACN (1:1), and (ii) H 2 O:MeOH (1:1). The mass spectrometer 5500 QTRAP (AB Sciex Inc., Framingham, MA) was set up in scheduled multiple reaction monitoring (MRM) mode which allows for the setup of detection windows around the peak of interest to improve sensitivity. The details of the MRM transitions can be found in Supplementary Table 1 .
Statistical Analysis
The non-parametric Mann-Whitney U test was used for comparing the levels of circulating endocannabinoids, and performed using GraphPad Prism v. 7.04 (GraphPad Software Inc., San Diego, CA). In order to compare the association between circulating endocannabinoids with brain CB1R availability, two methods were utilized: (i) partial least squares regression (PLS-R) modeling was used in order to combine multiple brain regions and circulating endocannabinoid measures.
This analysis was performed using PLS-Toolbox v. 8.6 (Eigenvector Research Inc., Manson, WA) and MATLAB 2017b (Mathworks Inc., Natick, MA). Due to the small number of samples, a leaveone-out cross-validation, using the number of iterations of the smallest group size, was utilized to ensure model validity. (ii) Spearman correlation coefficients were calculated using the statistical toolbox in MATLAB 2017b and p-values < 0.05 (two-tailed) were considered significant for the correlations. The individual spearman correlation coefficients (R) were illustrated as a heatmap using the 'corrplot' package for the R statistical programming language 51 . The individual correlations between the serum endocannabinoids and CB1R availability were plotted and analyzed using GraphPad Prism.
Generation of the statistical association brain maps
In order to visualize the associations of CB1R availability across different brain regions, the R 2 values from the individual brain regions arising from the PLS-R modelling were mapped onto the same brain template as the PET image analysis using MATLAB 2017b. The resultant image was then visualized using CARIMAS v. 2.9 (Turku PET Centre, Turku, Finland). The color scale for each brain region was defined by the healthy controls in each cohort and then applied to the FEP patients.
Results
Levels of circulating endocannabinoids
We measured a total of ten endocannabinoids and related structures (Supplementary Table 1) from serum of both HC and FEP patients from the two study sites. Considerable increases in AG were observed in some samples, which can be explained by variable freezing times 52 . These samples were excluded from subsequent analyses, resulting in the following available sample numbers: Turku (n = 10, HC; n = 8, FEP) and London (n = 11, HC; n = 15, FEP). In the Turku study, there was a reduction in circulating levels of arachidonic acid (AA; 140.6 ± 29.9 vs. 104.1 ± 26.8 ng/mL) and OEA (3.23 ± 1.04 vs. 2.29 ± 0.50 ng/mL) in the FEP patients (Figure 2a) . AA forms the backbone of two major endocannabinoids (AEA and 2-AG) 53 , and is released when they are broken down by fatty acid amide hydrolase (FAAH) 54 and monoacylglycerol lipase (MGL) 55 .
Therefore, the decreased levels of AA in FEP suggest reduced breakdown of these two metabolites. In line with this, there is a trend towards an increase in AG observed in the FEP group (2.32 ± 0.94 vs. 3.69 ± 2.02 ng/mL). Due to the use of serum, it was, however, not possible to differentiate between the levels of 1-AG and 2-AG, because of their rapid isomerization at room temperature. Therefore, only the concentrations of total AG are reported.
The same endocannabinoids were, however, not altered in patients with FEP in the London study (Figure 2b) . In Turku, patients had already started antipsychotic medication, whilst in London, the patients were mostly drug-naïve or free of pharmacological treatments 27 . Previous literature has shown that endogenous central elevations in anandamide (a CB1R agonist) found in patients with FEP 14, 56 are absent in patients taking antipsychotics 56 . Thus, antipsychotic treatment in the Turku sample may account for the differences we observe. However, this discrepancy may also be due to other differences between the study populations, such as diagnosis, substance use, diet or duration of illness.
Associations between central and peripheral endocannabinoid systems
Given the known role of the endocannabinoid system in dietary regulation 57 and weight gain 58 , we next investigated the associations between peripheral endocannabinoid levels and CB1R availability in the ROIs described in the methods.
Initially, we explored how circulating levels of endocannabinoids are associated with CB1R availability in the brain in both studies using PLS regression, which allowed us to see how all of the endocannabinoids are associated with individual brain regions in one model. The R 2 values were increased in healthy controls both in the Turku (Figure 3a) and London (Figure 3c) cohorts, as compared to the FEP group (Figure 3b, Turku and Figure 3d , London). We next explored the univariate associations between levels of circulating endocannabinoids and CB1R availability in the brain. Positive correlations of CB1R availability between the brain regions were observed in HCs from both study sites (Figure 3e) . Similarly, levels of circulating endocannabinoids were also positively correlated with each other in the healthy subjects (Figure   3e ). Interestingly, the levels of peripheral endocannabinoids and central CB1R availability were, conversely, negatively correlated in HCs in both Turku and London samples (Figure 3e) . In FEP subjects, CB1R availability was also positively correlated between the different brain regions (Figure 3f) . However, the degree of positive correlation between the circulating endocannabinoids was reduced (Figure 3f) .
Notably, the negative correlations between CB1R availability and levels of circulating endocannabinoids, as observed in HC, were absent in FEP patients (Figures 3e and 3f) . The loss of this association is more pronounced in the Turku study ( Supplementary Figure 1a-b) compared to the London study ( Supplementary Figure 1c-d) . This relative lack of association between central CB1R availability and circulating endocannabinoid levels in FEP suggests that there may normally be a functional link between these two systems, which may be dysregulated in FEP.
In order to further examine the associations between central CB1R availability and circulating peripheral endocannabinoids, we selected the brain region, from the available ROIs, with the highest R 2 value from the PLS-R modeling; the posterior cingulate cortex (Figure 3) . For the majority of serum endocannabinoids measured in FEP patients, there was a clear loss of any 13 negative correlation with CB1R availability, with few positive associations observed in the FEP patients (Figure 4) . This effect was more pronounced in the Turku study ( Supplementary   Figure 2a) , with similar trends observed in the London study, though these did not reach statistical significance (Supplementary Figure 2b) .
Discussion
We demonstrated that the cross-talk between the endocannabinoid networks in the brain and periphery are dysregulated in FEP, as compared to healthy controls. Reduced levels of AA and OEA in FEP subjects were observed in the Turku study, but not in London, where the patients were predominately drug-naïve or free from pharmacological treatments. A negative association between brain CB1R availability in the majority of the ROIs used in the PET imagiing and serum endocannabinoid levels was observed in healthy individuals, but not in FEP patients across the two independent cohorts of patients.
Endocannabinoids are lipid mediators with a vital role in the maintenance of metabolic and immune homeostasis 59, 60 . Several studies have found that systemic lipid profiles are dysregulated in various psychotic disorders 9, 61 . Our study corroborates these earlier findings, suggesting that the systemic ECS is dysregulated in psychosis 12, 29, 62 . In the periphery, a significant drop in the circulatory endocannabinoid, anandamide, was previously found to accompany the acute phase of Our previous data links rapid weight gain in FEP with elevated baseline levels of triglycerides of low carbon number and double bond count 9 , which are known to be associated with de novo lipogenesis, inhibition of lipolysis, and NAFLD 64, 65 . Endocannabinoids are known to stimulate de novo lipogenesis and obesity 66 . In our previous hepatic venous catheterization study in humans, we found elevated liver fat to be associated both with increased levels of 2-AG as well as higher splanchnic production of triglycerides of low carbon number and double bond count, suggesting that the ECS could contribute to the development of human NAFLD by affecting hepatic lipid metabolism 64 .
OEA is the monounsaturated analogue of AEA, but, unlike AEA, acts independently of the cannabinoid pathway, with no reported direct activity at the two known cannabinoid receptors, CB1R and CB2R 67 . OEA stimulates fat utilization as a peroxisome proliferator-activated receptor alpha (PPARα) agonist 68 . Activation of PPARα by OEA is known to induce satiety and regulate body weight 69 . A study in mice also suggests that OEA inhibits food intake by recruitment of the brain histaminergic system 70 . Our data suggest that decreased OEA in FEP subjects is likely the effect of antipsychotic meditation, as this was not seen in the cohort that was predominately unmedicated. Inhibition of lipolysis due to diminished OEA 69 may also contribute to increased liver fat, i.e., the accumulation of triacylglycerols in the liver, as observed by lipidomics in nonobese FEP patients who subsequently rapidly gained weight 9 . It is thus plausible that OEA levels are an early marker of propensity for FEP patients to gain weight. This hypothesis will clearly need to be examined prospectively, in a larger study setting.
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